JPH0237328B2 - - Google Patents

Info

Publication number
JPH0237328B2
JPH0237328B2 JP57132286A JP13228682A JPH0237328B2 JP H0237328 B2 JPH0237328 B2 JP H0237328B2 JP 57132286 A JP57132286 A JP 57132286A JP 13228682 A JP13228682 A JP 13228682A JP H0237328 B2 JPH0237328 B2 JP H0237328B2
Authority
JP
Japan
Prior art keywords
anagrelide
amount
dosage form
composition
platelet aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP57132286A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5826817A (ja
Inventor
Suchuaato Furemingu Junia Jeemuzu
Hooru Buinisukii Josefu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of JPS5826817A publication Critical patent/JPS5826817A/ja
Publication of JPH0237328B2 publication Critical patent/JPH0237328B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP57132286A 1981-07-30 1982-07-30 製薬組成物 Granted JPS5826817A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/288,639 US4357330A (en) 1981-07-30 1981-07-30 Pharmaceutical compositions
US288639 1988-12-21

Publications (2)

Publication Number Publication Date
JPS5826817A JPS5826817A (ja) 1983-02-17
JPH0237328B2 true JPH0237328B2 (enExample) 1990-08-23

Family

ID=23107996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57132286A Granted JPS5826817A (ja) 1981-07-30 1982-07-30 製薬組成物

Country Status (12)

Country Link
US (1) US4357330A (enExample)
JP (1) JPS5826817A (enExample)
AU (1) AU559161B2 (enExample)
BE (1) BE893974A (enExample)
CA (1) CA1181010A (enExample)
DE (1) DE3228402A1 (enExample)
FR (1) FR2510406B1 (enExample)
GB (1) GB2103090B (enExample)
IE (1) IE54277B1 (enExample)
LU (1) LU84306A1 (enExample)
MY (1) MY8800110A (enExample)
ZA (1) ZA825397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524051A1 (de) * 1985-07-05 1987-01-15 Hoechst Ag Kombinationspraeparate aus hemmstoffen der thrombozytenaggregation und deren verwendung
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
AT393962B (de) * 1987-10-22 1992-01-10 Thomae Gmbh Dr K Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US6194420B1 (en) 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AU2004206783B2 (en) * 2003-01-23 2009-03-26 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
CN101463035A (zh) * 2007-12-19 2009-06-24 华生制药私人有限公司 生产盐酸阿那格雷一水合物的改进方法
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
GB201017783D0 (en) 2010-10-21 2010-12-01 Shire Llc Process for the preparation of anagrelide and analogues thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2307538A1 (fr) * 1975-04-18 1976-11-12 Centre Etd Ind Pharma Nouveau medicament anti-agregant plaquettaire
US4124715A (en) 1977-05-16 1978-11-07 Jose Pozuelo Method of pharmacologically treating drug addiction with fusaric acid

Also Published As

Publication number Publication date
FR2510406B1 (fr) 1986-05-09
CA1181010A (en) 1985-01-15
FR2510406A1 (fr) 1983-02-04
IE821828L (en) 1983-01-30
DE3228402C2 (enExample) 1992-01-23
AU559161B2 (en) 1987-02-26
US4357330A (en) 1982-11-02
MY8800110A (en) 1988-12-31
AU8652782A (en) 1983-02-03
IE54277B1 (en) 1989-08-16
BE893974A (fr) 1983-01-31
JPS5826817A (ja) 1983-02-17
ZA825397B (en) 1983-06-29
DE3228402A1 (de) 1983-02-24
LU84306A1 (fr) 1983-04-13
GB2103090B (en) 1985-07-17
GB2103090A (en) 1983-02-16

Similar Documents

Publication Publication Date Title
JPH0237328B2 (enExample)
DE69636036T2 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
JP4509395B2 (ja) 肝臓疾患の予防治療薬
Satoh et al. Neuroprotective properties of a protein kinase inhibitor against ischaemia‐induced neuronal damage in rats and gerbils
US4132788A (en) Antiarthritic potentiation
US4444777A (en) Pharmaceutical compositions of anagrelide and sulfinpyrazone
EP0727994B1 (en) Antipyretic and analgesic methods and compositions containing optically pure r-etodolac
US20080234236A1 (en) Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
US4420483A (en) Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
Brogden et al. Fenoprofen: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
US4282215A (en) Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
AU2008247439A1 (en) Use of TP modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
GB1580444A (en) Pharmaceutical compositions
US4432980A (en) Pharmaceutical compositions
Segawa et al. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II
González‐Correa et al. Triflusal: an antiplatelet drug with a neuroprotective effect?
US4822789A (en) Method of producing renal function-improving effect and diuretic effect on warm-blooded animal
US4466963A (en) Pharmaceutical compositions
RU2191605C1 (ru) Анальгезирующее, спазмолитическое, противовоспалительное лекарственное средство
EP0006845B1 (en) Pharmaceutical composition comprising a 5-aroyl-1-c1-5 alkyl-pyrrole-2-acetic acid compound and acetaminophen or acetylsalicylic acid
EP0024690B1 (en) Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof
Nitelius et al. Pharmacokinetic interaction of acetylsalicylic acid and dipyridamole.
Tablets et al. Pr SILDENAFIL
Brampton PrRAN™-SILDENAFIL